Ocular Therapeutix Inc. (OCUL)
NASDAQ: OCUL
· Real-Time Price · USD
12.44
-0.21 (-1.66%)
At close: Aug 15, 2025, 2:33 PM
-1.66% (1D)
Bid | 12.43 |
Market Cap | 2.16B |
Revenue (ttm) | 56.6M |
Net Income (ttm) | -216.75M |
EPS (ttm) | -1.26 |
PE Ratio (ttm) | -9.87 |
Forward PE | -8.2 |
Analyst | Buy |
Ask | 12.44 |
Volume | 963,366 |
Avg. Volume (20D) | 2,358,935 |
Open | 12.67 |
Previous Close | 12.65 |
Day's Range | 12.39 - 12.68 |
52-Week Range | 5.79 - 12.91 |
Beta | 1.49 |
About OCUL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol OCUL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for OCUL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Ocular Therapeutix has released their quartely earnings
on Aug 5, 2025:
Next Earnings Release
Ocular Therapeutix Inc. is scheduled to release its earnings on
Nov 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-2.83%
Ocular Therapeutix shares are trading lower after ...
Unlock content with
Pro Subscription
2 months ago
+13.69%
Ocular Therapeutix shares are trading higher after the company announced that enrollment in the SOL-R registrational trial of its product candidate AXPAXLI in wet age-related macular degeneration will close this week.